US2004022816A1PendingUtilityA1
Fluid for haemofiltration
Priority: Sep 21, 2000Filed: Sep 21, 2001Published: Feb 5, 2004
Est. expirySep 21, 2020(expired)· nominal 20-yr term from priority
Inventors:Adrianus Antonius Hollander
A61K 31/7004A61P 13/12A61K 33/00A61K 31/194A61K 33/14A61K 33/06
19
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to a fluid suitable for use in haemofiltration, in particular for use in continuous veno-venous haemofiltration (CVVH). The fluid comprises an aqueous solution of physiologically acceptable salts containing at least Na+, Cl−, Mg2+, K+ and Ca2+ ions and optionally glucose, all in a physiologically acceptable concentration. The haemofiltration fluid is characterised in that the fluid contains the ions K+ in a concentration higher than 3 mmol/l and lower than 5.5 mmol/l and Ca2+ in a concentration lower than 1.5 mmol/l.
Claims
exact text as granted — not AI-modified1 . Haemofiltration fluid, in particular suitable for use in continuous veno-venous haemofiltration (CVVH), that comprises an aqueous solution of physiologically acceptable salts containing at least the Na + , Cl − , Mg 2+ , K + and Ca 2+ ions and optionally glucose, all in a physiologically acceptable concentration, characterised in that the haemofiltration fluid contains the ions K in a concentration higher than 3 mmol/l and lower than 5.5 mmol/l and Ca 2+ in a concentration lower than 1.5 mmol/l.
2 . Haemofiltration fluid according to claim 1 , characterised in that the K + concentration is between 3.5 and 5.5 mmol/l, preferably between 3.5 and 5 mmol/l.
3 . Haemofiltration fluid according to claim 1 or 2 , characterised in that the Cae+concentration is between 0.5 and 1.5 mmol/l, preferably between 0.8 and 1.3 mmol/l.
4 . Haemofiltration fluid according to one of the preceding claims, characterised in that the glucose concentration is between 0 and 15 mmol/l, preferably between 2 and 10 mmol/l and most preferentially between 3.5 and 8 mmol/l.
5 . Haemofiltration fluid according to one of the preceding claims, characterised in that the fluid comprises the following components in the indicated physiologically acceptable range:
Na +
135-145 mmol/l
Mg 2+
0.6-1.0 mmol/l
Cl −
95-120 mmol/l
Glucose
3.5-8 mmol/l
K +
3.5-5 mmol/l
Ca 2+
0.8-1.3 mmol/l
6 . Haemofiltration fluid according to one of the preceding claims, characterised in that the haemofiltration fluid further comprises citrate.
7 . Haemofiltration fluid according to claim 6 , characterised in that the citrate concentration is between 10 and 15 mmol/l.
8 . Haemofiltration fluid according to one of claims 1 - 5 , characterised in that the fluid further comprises at least one buffering compound.
9 . Haemofiltration fluid according to claim 8 , characterised in that the at least one buffering compound is a weak acid or bicarbonate or a mixture thereof.
10 . Haemofiltration fluid according to claim 8 or 9 , characterised in that the buffering compound is lactate.
11 . Haemofiltration fluid according to claim 10 , comprising:
Na +
140 mmol/l
Mg 2+
0.8 mmol/l
Cl −
108 mmol/l
K +
4 mmol/l
Ca 2+
1.2 mmol/l
Glucose
6 mmol/l
Lactate
40 mmol/l
12 . Haemofiltration fluid according to one of claims 8 or 9 , comprising:
Na +
140 mmol/l
Mg 2+
0.8 mmol/l
Cl −
118 mmol/l
K +
4 mmol/l
Ca 2+
1.2 mmol/l
Glucose
6 mmol/l
Bicarbonate
30 mmol/l
13 . Concentrate for the preparation of a haemofiltration fluid according to one of the preceding claims, by dilution with water, the concentrations of the components of which, after dilution, at the time of administration, are within the range of the concentrations of the components according to the preceding claims.
14 . Composition in non-dissolved form for the preparation of a haemofiltration fluid according to one of the preceding claims by dissolving the composition in water, the concentrations of the components of which, after dissolving, at the time of administration, are within the range of the concentrations of the components according to the preceding claims.
15 Use of the haemofiltration fluid according to one of the preceding claims for haemofiltration, preferably continuous veno-venous haemofiltration (CVVH).Join the waitlist — get patent alerts
Track US2004022816A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.